Protagonist Therapeutics (PTGX) EBT (2015 - 2026)

Protagonist Therapeutics has disclosed EBT across 12 years of filings, most recently posting $2.3 million for Q1 2026.

• EBT for Q1 2026 came in at $2.3 million, up 119.57% year-over-year; the trailing twelve-month figure through Mar 2026 was -$115.4 million (up 48.1% YoY), and the FY2025 annual result was -$129.3 million, down 446000.0% from the prior year.
• EBT came in at $2.3 million for Q1 2026 at Protagonist Therapeutics, up from -$43.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of $210.7 million in Q1 2024 to a low of -$145.7 million in Q4 2024.
• The 5-year median for EBT is -$33.7 million (2023), against an average of -$19.6 million.
• Peak annual rise in EBT reached 724.66% in 2024, while the deepest fall reached 633.07% in 2024.
• Protagonist Therapeutics' EBT stood at -$34.3 million in 2022, then soared by 179.78% to $27.3 million in 2023, then slumped by 633.07% to -$145.7 million in 2024, then soared by 70.0% to -$43.7 million in 2025, then surged by 105.22% to $2.3 million in 2026.
• The last three EBT figures came in at $2.3 million (Q1 2026), -$43.7 million (Q4 2025), and -$39.3 million (Q3 2025), per Business Quant data.